A
CLDX icon

AlphaQuest’s Celldex Therapeutics CLDX Stock Holding History

AlphaQuest’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,018
Closed -$218K – 410
2025
Q4 		$218K Buy
8,018
+4,316
+117% +$114K 0.01% 1400
2025
Q3 		$95.8K Sell
3,702
-9,254
-71% -$214K 0.01% 1745
2025
Q2 		$264K Buy
12,956
+844
+7% +$16.4K 0.03% 965
2025
Q1 		$220K Buy
12,112
+7,825
+183% +$175K 0.02% 936
2024
Q4 		$108K Buy
4,287
+2,705
+171% +$73.5K 0.01% 1069
2024
Q3 		$53.8K Sell
1,582
-5,801
-79% -$221K ﹤0.01% 1398
2024
Q2 		$273K Buy
7,383
+6,879
+1,365% +$260K 0.04% 663
2024
Q1 		$21.2K Buy
+504
New +$20.7K ﹤0.01% 1029

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

AlphaQuest's CLDX Position: Q1 2026 in Review

AlphaQuest sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 8,018 shares — an estimated $218K sold.

AlphaQuest first reported a position in CLDX in Q1 2024 and held it in 8 quarters. The position peaked at $273K in Q2 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • AlphaQuest reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 8,018 Celldex Therapeutics shares in Q1 2026, an estimated $218K.
  • AlphaQuest first reported a position in Celldex Therapeutics in Q1 2024 and held it in 8 quarters.
  • AlphaQuest's Celldex Therapeutics position peaked at $273K in Q2 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.